Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Berk

Showing results (141-150 of 163) with videos related to

Pageof 17
Sort By:
Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled TrialsLinda F Stein Gold, Michael T Jarratt, Alicia D Bucko, et al.
JAMA|May 12, 2005
Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohortDavid R Berk, Meira S Falkovitz-Halpern, David W Hill, et al.
Journal of the American Academy of Dermatology|February 8, 2018
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trialsLinda Stein-Gold, Leon H Kircik, Zoe Diane Draelos, et al.
Pediatric Dermatology|August 27, 2025
Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 YearsAdelaide A Hebert, Shireen V Guide, Vlada Groysman, et al.
Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
Pediatric Transplantation|September 3, 2011
Genotype, phenotype, and outcomes of nine patients with T-B+NK+ SCIDGrace P Yu, Kari C Nadeau, David R Berk, et al.
American Journal of Clinical Dermatology|November 12, 2022
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b TrialLinda Stein Gold, Javier Alonso-Llamazares, Zoe D Draelos, et al.
The New England Journal of Medicine|July 16, 2020
Trial of Roflumilast Cream for Chronic Plaque PsoriasisMark G Lebwohl, Kim A Papp, Linda Stein Gold, et al.
The British Journal of Dermatology|March 9, 2023
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trialZoe D Draelos, David N Adam, H Chih-Ho Hong, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
Pageof 17

Showing results (141-150 of 163) with videos related to

Sort By:
Pageof 17
Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled TrialsLinda F Stein Gold, Michael T Jarratt, Alicia D Bucko, et al.
JAMA|May 12, 2005
Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohortDavid R Berk, Meira S Falkovitz-Halpern, David W Hill, et al.
Journal of the American Academy of Dermatology|February 8, 2018
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trialsLinda Stein-Gold, Leon H Kircik, Zoe Diane Draelos, et al.
Pediatric Dermatology|August 27, 2025
Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 YearsAdelaide A Hebert, Shireen V Guide, Vlada Groysman, et al.
Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
Pediatric Transplantation|September 3, 2011
Genotype, phenotype, and outcomes of nine patients with T-B+NK+ SCIDGrace P Yu, Kari C Nadeau, David R Berk, et al.
American Journal of Clinical Dermatology|November 12, 2022
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b TrialLinda Stein Gold, Javier Alonso-Llamazares, Zoe D Draelos, et al.
The New England Journal of Medicine|July 16, 2020
Trial of Roflumilast Cream for Chronic Plaque PsoriasisMark G Lebwohl, Kim A Papp, Linda Stein Gold, et al.
The British Journal of Dermatology|March 9, 2023
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trialZoe D Draelos, David N Adam, H Chih-Ho Hong, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
Pageof 17